Neumora Therapeutics, Inc.
NMRA
$1.84
-$0.13-6.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -4.75% | -7.63% | 22.45% | -15.60% | 18.92% |
| Total Depreciation and Amortization | -60.87% | 21.05% | -87.90% | 0.00% | 0.64% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 25.85% | -29.02% | -11.22% | -7.91% | 2.15% |
| Change in Net Operating Assets | -28.42% | 158.96% | -1,348.38% | 61.28% | -104.61% |
| Cash from Operations | -2.83% | 11.01% | 11.85% | -18.09% | -50.34% |
| Capital Expenditure | 200.00% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -45.98% | 3.57% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -16.90% | 69.06% | -31.36% | 144.70% | -162.93% |
| Cash from Investing | -16.90% | 68.82% | -31.17% | 144.70% | -162.93% |
| Total Debt Issued | 28,702.21% | -100.74% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -- | -- | 774.03% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 200.00% |
| Cash from Financing | 43,311.76% | -100.74% | -- | -- | 917.18% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,075.44% | 228.11% | 76.78% | 88.55% | -206.82% |